Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study
Authors:
- Katherine J LeeKLKatherine J Lee
- D T DunnDDD T Dunn
- R GilsonRGR Gilson
- Kholoud PorterKPKholoud Porter
- L BansiLBL Bansi
- Teresa HillTHTeresa Hill
- A N PhillipsAPA N Phillips
- C A SabinCSC A Sabin
- Achim SchwenkASAchim Schwenk
- Clifford LeenCLClifford Leen
- Valerie DelpechVDValerie Delpech
- Jane AndersonJAJane Anderson
- 1 October 2008
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 22 (15) , 1943-1950
Abstract
To describe the time from first viral rebound on highly active antiretroviral therapy to first treatment change, identify factors associated with more rapid switching, and investigate whether treatment changes are in line with treatment guidelines. A multicentre cohort study. We described the time to first treatment switch among individuals experiencing confirmed virological rebound after initiating highly active antiretroviral therapy; factors associated with more rapid switching were identified using proportional hazards regression and predictors of a switch in line with guidelines were identified using logistic regression. Thirty-four percent of the 694 patients experiencing virological rebound remained on a failing regimen for more than 6 months. Factors associated with more rapid switching were lower CD4 cell count (hazard ratio, 0.84 /100 cells/μl higher, P < 0.001), higher viral load (1.29 /log10 copies/ml higher, P < 0.001), older age (1.06 /5 years older, P = 0.07), and changing/adding drugs to the regimen prior to rebound (1.16, P = 0.16). Two hundred and eighteen of the 394 treatment changes (55%) were in line with guidelines; those receiving nonnucleoside reverse transcriptase inhibitor-containing regimens were more likely to make changes in line with guidelines (adjusted odds ratio, 2.80, P < 0.001), whereas those who had previously added drugs to their regimen were less likely to make changes in line with guidelines (0.15, P = 0.001). A substantial minority of patients remain on a failing highly active antiretroviral therapy regimen for periods of 6 months or longer without adding new drugs. Changes made are often not in line with treatment guidelines, raising concerns about the development of resistance and long-term clinical outcomes in these individuals.Keywords
This publication has 27 references indexed in Scilit:
- Antiretroviral TherapyDrugs, 2008
- The Incidence of HIV Drug Resistance and Its Impact on Progression of HIV Disease Among Antiretroviral-Naïve Participants Started on Three Different Antiretroviral Therapy StrategiesHIV Research & Clinical Practice, 2007
- Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimenAIDS, 2007
- Evolution of HIV Resistance Mutations in Patients Maintained on a Stable Treatment Regimen After Virologic FailureJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAARTPLOS Medicine, 2006
- The Rate of Viral Rebound after Attainment of an HIV Load <50 Copies/mL According to Specific Antiretroviral Drugs in Use: Results from a Multicenter Cohort StudyThe Journal of Infectious Diseases, 2005
- The creation of a large UK‐based multicentre cohort of HIV‐infected individuals: The UK Collaborative HIV Cohort (UK CHIC) StudyHIV Medicine, 2004
- Cross-Resistance among Nonnucleoside Reverse Transcriptase Inhibitors Limits Recycling Efavirenz after Nevirapine FailureAIDS Research and Human Retroviruses, 2002
- Clinical, Biologic, and Behavioral Predictors of Early Immunologic and Virologic Response in HIV-Infected Patients Initiating Protease InhibitorsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapyHIV Medicine, 2000